Fintel reports that on September 19, 2024, Morgan Stanley initiated coverage of Myriad Genetics (NasdaqGS:MYGN) with a ...

Analyst Tejas Savant of Morgan Stanley maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price target of ...

At Myriad, we’re committed to partnering with genetic counselors in an effort to make genetic testing more accessible, affordable and easier to use for all patient populations,” said Susan Manley, ...

Myriad Genetics, Inc. (MYGN) stock saw a modest uptick, ending the day at $28.6 which represents a slight increase of $0.70 or 2.51% from the prior close of $27.9. The stock opened at $27.94 and ...

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in ...

Wells Fargo has recently initiated Myriad Genetics, Inc. (MYGN) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated ...

Myriad Genetics, Inc. (NASDAQ: MYGN) reported adjusted earnings of 5 cents per share in the second quarter of 2024 compared to the Zacks Consensus Estimate of a loss of 1 cent per share.

Myriad Genetics Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has discontinued part of its economic utility study concerning GeneSight ...

A month has gone by since the last earnings report for Myriad Genetics (MYGN). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

On September 9, 2024, Heinrich Dreismann, a Director at Myriad Genetics Inc (NASDAQ:MYGN), executed a sale of 10,000 shares of the company. The transaction was documented in a recent SEC Filing.

Short interest in Myriad Genetics Inc (NASDAQ:MYGN) increased during the last reporting period, rising from 3.84M to 4.39M. This put 6.77% of the company's publicly available shares short.

Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.08 per share a year ago.